Ascletis Reports Stronger Weight-Loss Results With Dual Agonist Combo

Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity

Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese…

Ascletis Reports Stronger Weight-Loss Results With Dual Agonist Combo

HONG KONG, Aug. 18, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, in combination with ASC31, its in-house developed GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual targeting peptide agonist drug candidate. ASC31 is an in-house discovered and developed novel peptide agonist …